Metropolitan Life Insurance Company (MetLife)’s Trillium Therapeutics Inc. TRIL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-29,523	Closed	-$518K	–	2884
2021 Q3	$518K	Hold	29,523	–	–	0.01%	1437
2021 Q2	$286K	Buy	+29,523	New	+$278K	﹤0.01%	1894

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TRIL Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 29,523 shares — an estimated $518K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $518K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 29,523 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $518K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
Metropolitan Life Insurance Company (MetLife)'s Trillium Therapeutics Inc. position peaked at $518K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.